Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17498424 | 0.80 | IDO1 (0.53) | ALDH1A1 | |
| SCHEMBL9072649 | 0.77 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAGFERCYP1A2 | |
| SCHEMBL12305615 | 0.77 | MAPT (0.40) | ALDH1A1MAPTLMNAGFERCYP1A2 | |
| SCHEMBL13462780 | 0.77 | POLB (0.44) | ALDH1A1MAPTLMNAGFERCYP1A2 | |
| SCHEMBL2668504 | 0.77 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAGFERCYP1A2 | |
| SCHEMBL10297528 | 0.73 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNAGFERCYP1A2 | |
| SCHEMBL16417615 | 0.67 | ALDH1A1 (0.33) | ALDH1A1MAPTLMNAGFERCYP1A2 | |
| SCHEMBL18266955 | 0.67 | CCNC (0.41) | — | |
| SCHEMBL10200851 | 0.67 | CCR1 (0.45) | ALDH1A1CYP1A2CYP2C19HTTL3MBTL1 | |
| SCHEMBL13087805 | 0.67 | NOS3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-8933077-B2 | Glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8431713-B2 | 2-aminopyridine derivatives as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120030841-A1 | Isoxazoline compounds for combating invertebrate pests | BASF SE (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | ALDH1A1 1869/4885MAPT 4375/4885LMNA 1829/4885 |
| US-20120030841-A1 | Isoxazoline compounds for combating invertebrate pests | PRDX5, PRDX1, PRDX2 | ALDH1A1 2028/4885MAPT 1696/4885LMNA 2762/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | ALDH1A1 2267/4885MAPT 120/4885LMNA 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.